# ATRA catalysts: Atara Biotherapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/atra/catalysts

> Atara Biotherapeutics, Inc. (ATRA) has 1 upcoming catalyst. The next is the Tab-cel (tabelecleucel) PDUFA date, March 31, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for ATRA?

Atara Biotherapeutics, Inc. (ATRA) has 1 upcoming catalyst. The next is the Tab-cel (tabelecleucel) PDUFA date, March 31, 2027. SEC Form 10-Q: "Tab-cel (tabelecleucel) is currently in Phase 3 development in the U.S. In September 2026, Pierre Fabre resubmitted the BLA for tab-cel, and in October 2026, the FDA accepted the resubmission for a Class 2 review with a target action date of March 31, 2027." [Calendar and source filings](https://sec-api.dev/companies/atra/catalysts)

Source: SEC Form 10-Q, accession 0001104659-26-125192, https://www.sec.gov/Archives/edgar/data/1604464/000110465926125192/tmb-20260930x10q.htm (retrieved 2026-11-12). Last confirmed 2026-11-10. Cite: https://sec-api.dev/companies/atra/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Atara Biotherapeutics, Inc. |
| Ticker | ATRA (Nasdaq) |
| SEC CIK | 1604464 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/atra |

## Cash runway

Cash $9.9M as of 2026-09-30; quarterly burn $879K; about 33.8 months of runway at that rate (XBRL company facts, accession 0001104659-26-125192).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 8, 2024 | [Atara Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/atra/catalysts) | ATRA |  | completed | "Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000095017024125334/atra-ex99_1.htm)) |
| Q1 2025 | [ATA3219 interim data readout](https://sec-api.dev/pdufa/ata3219) | ATRA |  | scheduled | "We treated the first patient and continue to open sites and initiate enrollment of patients in our multi-center, Phase 1 open-label, dose escalation clinical trial for ATA3219 in NHL, including large B-cell lymphomas, follicular lymphoma, or mantle cell lymphoma, with initial clinical data anticipated in the first quarter of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1604464/000095017024125389/atra-20240930.htm)) |
| Jan 2025 | [ATA3219 complete response letter (CRL)](https://sec-api.dev/pdufa/ata3219) | ATRA |  | completed, complete response letter | "Atara received a clinical hold notice from FDA on EBVALLO studies linked to the CRL in January 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000095017025035482/atra-ex99_1.htm)) |
| January 15, 2025 | [Tab-cel (tabelecleucel) PDUFA date](https://sec-api.dev/pdufa/tabelecleucel) | ATRA |  | completed, complete response letter | "Tab-cel® U.S. BLA On-Track With PDUFA Target Action Date of January 15, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000095017024125334/atra-ex99_1.htm)) |
| January 15, 2025 | [Tab-cel (tabelecleucel) complete response letter (CRL)](https://sec-api.dev/pdufa/tabelecleucel) | ATRA |  | completed, complete response letter | "COMPLETE RESPONSE letter dated 01/15/2025 for BL 125745 to Atara Biotherapeutics, Inc.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125745_20250115.pdf%22)) |
| January 16, 2025 | [EBVALLOTM (ebvallotm) complete response letter (CRL)](https://sec-api.dev/pdufa/ebvallotm) | ATRA |  | completed, complete response letter | "The clinical hold was directly linked to GMP compliance issues identified during the pre-license inspection of the third-party manufacturing facility referenced in the Complete Response Letter (CRL) for EBVALLOTM that was announced on January 16, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000119312525113811/d905721dex991.htm)) |
| March 7, 2025 | [Atara Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/atra/catalysts) | ATRA |  | completed | "Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000095017025035482/atra-ex99_1.htm)) |
| Apr 2025 | [EBVALLOTM (ebvallotm) complete response letter (CRL)](https://sec-api.dev/pdufa/ebvallotm) | ATRA |  | completed, complete response letter | "In April 2025, Atara paused its review of strategic options, pending the Type A meeting with the FDA which is scheduled in the second quarter of 2025, to discuss the plan to address the issues raised by the FDA in the CRL and the path forward for resubmission of the EBVALLOTM BLA." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000119312525120345/d106735dex991.htm)) |
| mid-2025 | [ATA3219 interim data readout](https://sec-api.dev/pdufa/ata3219) | ATRA | systemic lupus erythematosus | scheduled | "Atara expects to initiate a Phase 1 study of ATA3219 as a monotherapy for the treatment of systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis [LN]) by end of year with initial clinical data anticipated in mid-2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000095017024125334/atra-ex99_1.htm)) |
| mid-2025 | [ATA3219 trial start](https://sec-api.dev/pdufa/ata3219) | ATRA | systemic lupus erythematosus | scheduled | "Atara expects to initiate a Phase 1 study of ATA3219 as a monotherapy for the treatment of systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis [LN]) by end of year with initial clinical data anticipated in mid-2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000095017024125334/atra-ex99_1.htm)) |
| May 14, 2025 | [Atara Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/atra/catalysts) | ATRA |  | completed | "Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000119312525120345/d106735dex991.htm)) |
| July 14, 2025 | [Tab-cel (tabelecleucel) NDA/BLA submission](https://sec-api.dev/pdufa/tabelecleucel) | ATRA | cancer and autoimmune diseases, today | completed | "THOUSAND OAKS, Calif.(BUSINESS WIRE) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has resubmitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel (EBVALLO or tab-cel®) indicated as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000119312525158719/d63996dex991.htm)) |
| August 11, 2025 | [Atara Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/atra/catalysts) | ATRA |  | completed | "Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000095017025106533/atra-ex99_1.htm)) |
| November 12, 2025 | [Atara Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/atra/catalysts) | ATRA |  | completed | "Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000119312525276209/d66575dex991.htm)) |
| Jan 2026 | [ATA3219 complete response letter (CRL)](https://sec-api.dev/pdufa/ata3219) | ATRA |  | completed, complete response letter | "In January 2026, we received the Second Complete Response Letter claiming that the ALLELE trial, previously confirmed by the FDA as adequate to support the BLA filing, is no longer considered to be an adequate and well-controlled study due to deficiencies in study design," ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1604464/000110465926125192/tmb-20260930x10q.htm)) |
| January 10, 2026 | [Tab-cel (tabelecleucel) PDUFA date](https://sec-api.dev/pdufa/tabelecleucel) | ATRA |  | completed, complete response letter | "Tab-cel Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000119312525276209/d66575dex991.htm)) |
| January 12, 2026 | [Tab-cel (tabelecleucel) complete response letter (CRL)](https://sec-api.dev/pdufa/tabelecleucel) | ATRA | relapsed or refractory EBV+ PTLD | completed, complete response letter | "Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000119312526010342/d34257dex991.htm)) |
| March 16, 2026 | [Atara Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/atra/catalysts) | ATRA |  | completed | "Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000119312526108344/atra-ex99_1.htm)) |
| March 23, 2026 | [Tab-cel (tabelecleucel) FDA approval](https://sec-api.dev/pdufa/tabelecleucel) | ATRA |  | completed, approved | "For example, on March 23, 2026, a putative securities class action captioned Kuang v. Atara Biotherapeutics, Inc., et al. was filed against us and certain of our current and former officers asserting claims based on alleged misstatements and omissions relating to manufacturing issues, the Phase 3 ALLELE study of tab-cel, and the likelihood of FDA approval of the tab-cel BLA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1604464/000110465926125192/tmb-20260930x10q.htm)) |
| August 12, 2026 | [Atara Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/atra/catalysts) | ATRA |  | completed | "Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000119312526346857/atra-ex99_1.htm)) |
| November 10, 2026 | [Atara Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/atra/catalysts) | ATRA |  | completed | "Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000110465926125171/tmb-ex99d1.htm)) |
| March 31, 2027 | [Tab-cel (tabelecleucel) PDUFA date](https://sec-api.dev/pdufa/tabelecleucel) | ATRA |  | scheduled | "Tab-cel (tabelecleucel) is currently in Phase 3 development in the U.S. In September 2026, Pierre Fabre resubmitted the BLA for tab-cel, and in October 2026, the FDA accepted the resubmission for a Class 2 review with a target action date of March 31, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1604464/000110465926125192/tmb-20260930x10q.htm)) |

## Drugs

- [ATA3219](https://sec-api.dev/pdufa/ata3219): systemic lupus erythematosus
- [EBVALLOTM (ebvallotm)](https://sec-api.dev/pdufa/ebvallotm): 
- [Tab-cel (tabelecleucel)](https://sec-api.dev/pdufa/tabelecleucel): relapsed or refractory ebv+ ptld, cancer and autoimmune diseases, today

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/atra/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ATRA catalysts: Atara Biotherapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/atra/catalysts

```bibtex
@misc{secapidev_companies_atra_catalysts_20261116,
  title        = {ATRA catalysts: Atara Biotherapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/atra/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_atra_catalysts_20261116","title":"ATRA catalysts: Atara Biotherapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/atra/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
